Novo, Eventide Asset Management and Wellington Management led a $120m Series C round for Freeline.

Novo, Eventide Asset Management and Wellington Management led a $120m Series C round for Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, with additional participation from Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund. "The potential of gene therapy to change patients’ lives has never been greater and we are delighted to have leading US and European biotechnology investors join us in this extended Series C financing. It comes at an exciting time for Freeline with our lead program in Haemophilia B progressing through clinical development, and with promising programs behind that, including a gene therapy treatment for Fabry Disease in the clinic and for Gaucher Disease and Haemophilia A in late preclinical development," Theresa Heggie, Freeline CEO.